Evaluation of synovial angiogenesis in patients with rheumatoid arthritis using 68Ga-PRGD2 PET/CT: A prospective proof-of-concept cohort study

Annals of the Rheumatic Diseases

Volumn 73, Issue 6, 2014, Pages 1269-1272

  Zhu, Zhaohui ^a   Yin, Yufeng ^a   Zheng, Kun ^a   Li, Fang ^a   Chen, Xiaoyuan ^b   Zhang, Fengchun ^a   Zhang, Xuan ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GALLIUM 68; PRGD2 GA 68; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR;

ADULT; ANGIOGENESIS; ARTHRITIS; ARTICLE; CLINICAL ARTICLE; CLINICAL DISEASE ACTIVITY INDEX; COHORT ANALYSIS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ACTIVITY; DISEASE DURATION; DISEASE SEVERITY; DRUG ACCUMULATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; INFLAMMATION; INTERMETHOD COMPARISON; LYMPH NODE; MALE; MUSCLE; NEOVASCULARIZATION (PATHOLOGY); OSTEOARTHRITIS; PAIN; PRIORITY JOURNAL; PROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SYNOVIAL ANGIOGENESIS; SYNOVIUM; TREATMENT RESPONSE;

ARTHRITIS; DISEASE ACTIVITY; RHEUMATOID ARTHRITIS;

ADULT; ARTHRITIS, RHEUMATOID; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; FLUORODEOXYGLUCOSE F18; GADOLINIUM; HUMANS; MALE; MIDDLE AGED; MULTIMODAL IMAGING; NEOVASCULARIZATION, PATHOLOGIC; POSITRON-EMISSION TOMOGRAPHY; RADIOISOTOPES; RADIOPHARMACEUTICALS; SYNOVIAL MEMBRANE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84899830608     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-204820     Document Type: Article

References (20)

1. Koch AE. Angiogenesis as a target in rheumatoid arthritis. Ann Rheum Dis 2003;62 (suppl 2):ii60-7.
2. Conaghan PG, O'Connor P, McGonagle D, et al. Elucidation of the relationship between synovitis and bone damage: a randomized magnetic resonance imaging study of individual joints in patients with early rheumatoid arthritis. Arthritis Rheum 2003;48: 64-71. (Pubitemid 36091649)
3. Hynes RO. Integrins: versatility, modulation, and signaling in cell adhesion. Cell 1992;69: 11-25.
4. Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 1994;264: 569-71.
5. Niu G, Chen X. Why integrin as a primary target for imaging and therapy. Theranostics 2011;1: 30-47.
6. Zhu Z, Miao W, Li Q, et al. 99mTc-3PRGD2 for integrin receptor imaging of lung cancer: a multicenter study. J Nucl Med 2012;53: 716-22.
7. Chen X, Liu S, Hou Y, et al. MicroPET imaging of breast cancer alphav-integrin expression with 64Cu-labeled dimeric RGD peptides. Mol Imaging Biol 2004;6: 350-9. (Pubitemid 39243068)
8. Wilder RL. Integrin alpha V beta 3 as a target for treatment of rheumatoid arthritis and related rheumatic diseases. Ann Rheum Dis 2002; 61(suppl 2):ii96-9. (Pubitemid 35221729)
9. Storgard CM, Stupack DG, Jonczyk A, et al. Decreased angiogenesis and arthritic disease in rabbits treated with an alphavbeta3 antagonist. J Clin Invest 1999;103: 47-54. (Pubitemid 29031162)
10. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31: 315-24. (Pubitemid 18091653)
11. Aletaha D, Smolen J. The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol 2005;23:S100-8. (Pubitemid 46657517)
12. Naredo E, Collado P, Cruz A, et al. Longitudinal power Doppler ultrasonographic assessment of joint inflammatory activity in early rheumatoid arthritis: predictive value in disease activity and radiologic progression. Arthritis Rheum 2007;57: 116-24.
13. Goerres GW, Forster A, Uebelhart D, et al. F-18 FDG whole-body PET for the assessment of disease activity in patients with rheumatoid arthritis. Clin Nucl Med 2006;31: 386-90. (Pubitemid 44315517)
14. Elzinga EH, van der Laken CJ, Comans EF, et al. 18F-FDG PET as a tool to predict the clinical outcome of infliximab treatment of rheumatoid arthritis: an explorative study. J Nucl Med 2011;52: 77-80.
15. Okamura K, Yonemoto Y, Arisaka Y, et al. The assessment of biologic treatment in patients with rheumatoid arthritis using FDG-PET/CT. Rheumatology (Oxford) 2012;51: 1484-91.
16. Izuishi K, Yamamoto Y, Sano T, et al. Molecular mechanism underlying the detection of colorectal cancer by 18F-2-fluoro-2-deoxy-D-glucose positron emission tomography. J Gastrointest Surg 2012;16: 394-400.
17. Lang L, Li W, Guo N, et al. Comparison study of [18F]FAl-NOTA-PRGD2, [18F] FPPRGD2, and [68Ga]Ga-NOTA-PRGD2 for PET imaging of U87MG tumors in mice. Bioconjug Chem 2011;22: 2415-22.
18. Guo N, Lang L, Li W, et al. Quantitative analysis and comparison study of [18F] AlF-NOTA-PRGD2, [18F]FPPRGD2 and [68Ga]Ga-NOTA-PRGD2 using a reference tissue model. PLoS ONE 2012;7:e37506.
19. Seldin DW, Habib I, Soudry G. Axillary lymph node visualization on F-18 FDG PET body scans in patients with rheumatoid arthritis. Clin Nuclear Med 2007;32: 524-26. (Pubitemid 46986079)
20. Johnson BA, Haines GK, Harlow LA, et al. Adhesion molecule expression in human synovial tissue. Arthritis Rheum 1993;36: 137-46. (Pubitemid 23059324)